(Sharecast News) - Denmark's Genmab said on Monday that it has agreed to buy Dutch drugmaker Merus for $8bn.
Merus is a clinical-stage biotechnology company with its late-stage breakthrough therapy asset petosemtamab in Phase 3 development. Petosemtamab is an EGFRxLGR5 bispecific antibody with the potential to be both first- and best-in-class...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE